Insulet Corporation Announces Departure of Two Key Board Members

Details

Scannell, a member of the Board of Directors, has decided to step down for health reasons, effective immediately. Additionally, Michael R. Minogue notified the Company of his decision to step down from the Board to focus on his candidacy for Governor of Massachusetts, effective September 15, 2026. Neither departure is due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Board and management extend their sincere appreciation to both for their leadership and contributions during their service.

Items reported

About Insulet Corporation

Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.